Unfortunately, immune-related adverse events have been associated with anti-CTLA4 antibodies including the following: vitiligo, colitis, hepatitis, endocrinopathies, inflammatory polyneuropathies, myasthenia gravis, and immune-mediated cytopenia [14]. The gene discussed is CTLA4; the disease is colitis.